Display options
Cite
Westerberg PA, Linde T, Vanderschueren D, et al. Oncogenic osteomalacia illustrating the effect of fibroblast growth factor 23 on phosphate homeostasis. Clin Kidney J. 2012;5(3):240-3doi: 10.1093/ckj/sfs031.
Westerberg, P. A., Linde, T., Vanderschueren, D., Billen, J., Jans, I., & Ljunggren, �. �. (2012). Oncogenic osteomalacia illustrating the effect of fibroblast growth factor 23 on phosphate homeostasis. Clinical kidney journal, 5(3), 240-3. https://doi.org/10.1093/ckj/sfs031
Westerberg, Per-Anton, et al. "Oncogenic osteomalacia illustrating the effect of fibroblast growth factor 23 on phosphate homeostasis." Clinical kidney journal vol. 5,3 (2012): 240-3. doi: https://doi.org/10.1093/ckj/sfs031
Westerberg PA, Linde T, Vanderschueren D, Billen J, Jans I, Ljunggren Ö. Oncogenic osteomalacia illustrating the effect of fibroblast growth factor 23 on phosphate homeostasis. Clin Kidney J. 2012 Jun;5(3):240-3. doi: 10.1093/ckj/sfs031. Epub 2012 Mar 29. PMID: 26069775; PMCID: PMC4400509.
Copy Download .nbib Format: NLM
Share it on

Clin Kidney J. 2012 Jun;5(3):240-3. doi: 10.1093/ckj/sfs031. Epub 2012 Mar 29.

Oncogenic osteomalacia illustrating the effect of fibroblast growth factor 23 on phosphate homeostasis.

Clinical kidney journal

Per-Anton Westerberg, Torbjörn Linde, Dirk Vanderschueren, Jaak Billen, Ivo Jans, Östen Ljunggren

Affiliations

  1. Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  2. Laboratory of diagnostic medicine, Katholieke Universiteit Leuven, Leuven, Belgium ; laboratory of experimental medicine and endocrinology, Katholieke Universiteit Leuven, Leuven, Belgium.

PMID: 26069775 PMCID: PMC4400509 DOI: 10.1093/ckj/sfs031

Abstract

In oncogenic osteomalacia (OOM), fibroblast growth factor 23 (FGF23) induces renal phosphate wasting and inhibits the appropriate increase of calcitriol. A patient suffering from OOM is described. Serum calcium, phosphate, biointact parathyroid hormone and intact FGF23 as well as the calcitriol and 24,25-vitamin D levels were measured before and after tumour removal. The clinical approach to a patient with hypophosphataemia is discussed and the changes in mineral metabolism after removal of a FGF23-producing tumour are described.

Keywords: FGF23; mineral metabolism; osteomalacia; phosphate

References

  1. Nat Genet. 2000 Nov;26(3):345-8 - PubMed
  2. Kidney Int. 2010 Sep;78(5):463-72 - PubMed
  3. J Clin Invest. 1984 Jun;73(6):1580-9 - PubMed
  4. Bone. 2008 Jun;42(6):1235-9 - PubMed
  5. Endocr Relat Cancer. 2011 Jun 08;18(3):R53-77 - PubMed
  6. J Clin Endocrinol Metab. 2010 Apr;95(4):1846-50 - PubMed
  7. J Clin Endocrinol Metab. 2002 Nov;87(11):4957-60 - PubMed
  8. Am J Surg Pathol. 2004 Jan;28(1):1-30 - PubMed
  9. N Engl J Med. 2003 Apr 24;348(17):1656-63 - PubMed
  10. N Engl J Med. 2010 Mar 25;362(12):1102-9 - PubMed
  11. J Bone Miner Res. 2009 Nov;24(11):1879-88 - PubMed
  12. Am J Hum Genet. 2006 Feb;78(2):179-92 - PubMed
  13. J Bone Miner Metab. 2012 Jan;30(1):1-9 - PubMed
  14. Curr Opin Nephrol Hypertens. 2011 Jul;20(4):337-44 - PubMed
  15. Eur J Mass Spectrom (Chichester). 2010;16(1):81-9 - PubMed
  16. J Clin Invest. 1986 Jan;77(1):7-12 - PubMed
  17. Curr Opin Nephrol Hypertens. 2008 Jul;17(4):363-7 - PubMed
  18. Am J Kidney Dis. 2012 Jan;59(1):152-9 - PubMed

Publication Types